ArticleNeuro-oncology advances

Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.

Nikola Mikic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.